Internet addiction disorder is not an official psychological diagnosis but treatments exist
Before COVID hit, Jillian, 68, didn't have internet access at her home — not because she couldn't get it connected, but because she was afraid of what might happen if she did.
"I initially got onto the internet at the library to look up real estate because I was thinking of moving and even then, I was aware that I seemed to linger on it," she tells ABC Radio National's series Brain Rot.
The internet's irresistible pull was enough to keep her browsing confined to the local library.
Then in 2020, when parts of the country went into lockdown, Jillian could no longer access her local library, so she decided to get Wi-Fi at home.
And that's when she felt her internet use became chronic.
"I spent hours alone at home looking at my phone," she says.
"At the time I called it 'internet research' but it was just trivial news that was consuming me."
She tried to limit her internet use but found that one quick search would inevitably lead to another and another.
They sound like behaviours associated with an addiction. Yet the term "internet addiction" is not formally recognised as it's not listed as a diagnosis in the Diagnostic and Statistical Manual of Mental Disorders.
And the medical community is divided as to whether the term should be classified as a diagnosis.
Regardless of the current classification, some people report feeling addicted to online activities. Depending on the individual, that could be endless online shopping, gaming, social media use or video streaming.
Before delving into treatments for what many call internet addiction, it's worth examining just how online we've become.
A decade ago, around a third of the world's population used the internet. That figure has since doubled.
And recent evidence suggests the COVID pandemic drove an uptick in screen time globally too. A 2022 meta-analysis of 89 studies, collectively analysing data from more than 200,000 people, found spikes in screen time across the board during the pandemic.
The increase was highest in primary school kids, whose screen time went up by 1.4 hours a day. Adult screen time increased by an hour each day compared to pre-pandemic use.
Whether that screen time has fallen back to pre-COVID levels isn't yet known. Increased internet use does not, however, automatically mean it becomes an addiction.
So: is it possible to be addicted to the internet?
Anna Lembke, a psychiatrist in addiction medicine at Stanford University School of Medicine, thinks so.
She explains that all addictions — whether they're due to substances or behaviours — operate using the brain pathway responsible for processing reward and motivation.
"Basically when we do something rewarding or pleasurable or just simply something that our brain recognises as important for survival, our brain releases dopamine in the reward pathway.
And many digital platforms were designed to elicit quick dopamine bursts, Professor Lembke adds.
"They were made to make [device use] frictionless and easy for us to access the content and very difficult to get off because of the reinforcing nature of the medium itself.
"Most people who use digital media will not go on to develop a severe and life-threatening digital media addiction.
"But a vulnerable subset will, and it's probably going to shake out at around the same 10 per cent that we see for addiction to drugs and alcohol."
And while there is no official diagnosis for internet addiction, Anastasia Hronis, clinical psychologist and researcher at University of Technology Sydney, agrees with Professor Lembke.
"It's not yet a diagnosable condition but the evidence emerging is certainly telling us that children, teens and adults can certainly become hooked and experience some sort of harm as a result of using their phone," she says.
Others in the field aren't confident that the current level of evidence justifies an official "internet addiction disorder" diagnosis yet.
Dar Meshi, who researches social media use and mental health at Michigan State University, thinks there's "some compelling evidence right now but … some of the evidence hasn't reached the levels of proof".
He also warns "we shouldn't throw the baby out with the bath water" by insisting that all internet use is "bad" until we know more.
While the field of internet use research into problematic internet use has grown significantly in recent years, it's still taking shape.
But generally, treatment for problematic internet use or internet addiction — whatever you might call it — draws on the principles of addiction treatments, Dr Hronis says.
"We know that the treatments are somewhat similar when it comes to working with people who have addictions as well. The target of the addiction might change, but the fundamental principles around helping someone through an addiction are similar."
South Korea has been considered a world leader in tackling problematic internet use. In 2002, the nation — of which 97 per cent of the population use the internet — established a network of "digital detox" camps that mostly cater to children and teenagers.
Participants have their phones removed for the entire 12-day camp. The aim of the treatment is to increase human interaction and decrease periods spent online.
Elsewhere around the world, private treatment facilities have also sprung up.
In 2008, US psychologist Hilarie Cash and a colleague opened reSTART, a residential treatment facility for people they believed needed a higher level of care to treat their video game addiction, internet gaming, excessive screen-time and social media use.
Dr Cash says she has been treating clients with what she describes as internet addiction disorder since the mid-90s.
"At the time I knew nothing about the internet … I didn't own a computer.
ReSTART operates on a rural property in Washington, and, like the South Korean digital detox camps, there are no phones allowed.
"When our clients come, they are abstinent from screens and the internet for three months or longer … we believe total abstinence is extremely important," Dr Cash says.
Clients generally find the first month of treatment the most difficult, she adds: "The brain is going through the process that is recognised as withdrawal … once that process is finished they are typically just feeling so much better, they're more relaxed and just starting to be able to enjoy life once again."
However, there are no reliable statistics on how well this kind of addiction-focused treatment works for internet overuse.
As the pandemic started to tail off, Jillian, who has been a member of Alcoholics Anonymous since her late 20s, "recognised the same feelings of addiction and the need to do something about it."
That's how she stumbled upon Internet and Technology Addicts Anonymous (ITAA), which formed in 2017 and has more than 3,000 members worldwide.
The program is closely modelled on Alcoholics Anonymous. According to its website "it's a 12-step fellowship of individuals who support each other in recovering from internet and technology addiction" and members are encouraged to attend regular free online support meetings.
Thanks to ITAA, Jillian has been "sober" from the internet for more than two years.
Listen to the full episode of Brain Rot about problematic internet use, and subscribe to the podcast for more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
an hour ago
- News.com.au
Health Check: Paradigm makes scenic acquisitive detour, but it's no strategic shift
Paradigm Biopharmaceuticals will spend up to $16.5 million on an oral drug asset, but stays focused on its phase III knee trial Percheron enters headline $450 million cancer drug acquisition Neurizon goes from solid to liquid with its motor neurone disease drug candidate Paradigm Biopharmaceuticals (ASX:PAR) is taking the acquisitive scenic route in its quest to develop an effective knee osteoarthritis treatment, but says it remains focused on its phase III knee trial. In a heavily back-ended deal, Paradigm will pay as much as $16.5 million to purchase Proteobioactives Pty Ltd. This company owns an early-stage oral candidate for minor to mild osteoarthritis (OA), called Pentacoxib. The proposed drug combines pentosan polysulfate sodium (PPS) – Paradigm's core asset – with a COX-2 inhibitor (Coxib). The idea is to improve drug 'bioavailability': a shortcoming of many oral drugs. The deal expands Paradigm's remit into the OA-related pain market, such as hand OA, mild knee OA and the veterinary market (dogs and horses). Proof of concept data shows meaningful pain reduction in patients with hand and knee OA. 'Strategic alignment' Paradigm touts Pentacoxib as an alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), which are 'not known to improve structures of the arthritic joint'. Paradigm dubs the purchase as a 'strategic alignment' with its core program, which is about developing its repurposed PPS (Zilosul) for moderate to severe knee OA. The acquired asset moves the company down the OA 'severity spectrum' and maintains Paradigm's focus on a non-opioid alternative. Proteobioactives was founded by Professor Peter Ghosh, who pioneered PPS research. The deal gives Paradigm exclusive global rights to develop and commercialise the PPS-Coxib combo for pain and inflammation. The acquisition enables 'potential expansion into earlier-stage disease segments where large unmet needs remain.' Now to the financial nitty gritty: The deal involves an upfront $500,000 in cash and a $1 million milestone payment on completion of a phase II trial. Paradigm pays a further $5 million on 'successful completion' of a phase III trial. A further $5 million is paid on US Food & Drug Administration approval. There's more! Another $5 million is due on the sale of an FDA registered product, 'as evidenced by the submission of a sales invoice, proof of delivery, or other relevant documentation". Keep your receipts guys! The deal is modest bet for Paradigm relative to its long-awaited phase III knee OA. The study in underway across up to 15 Australian and 50 US sites. Percheron finds a new purpose Having scoured for a new asset following the failure of its flagship clinical program, Percheron Therapeutics (ASX:PER) has settled on a Singapore-based cancer drug candidate. This is by way of an exclusive license agreement with Hummingbird Bioscience, for a monoclonal antibody therapy with potential applications in several cancers. Percheron hopes to start a clinical trial of the candidate, dubbed HMBD-002, next year. Percheron will pay Hummingbird an upfront US$ 3 million ($4.6 million), with contingent milestone payments of up to US$287 million ($443 million), plus royalties to boot. Naturally, the big bucks are later in the piece. Taking in the VISTA HMBD-002 targets a bodily agent called VISTA, as in 'v-domain immunoglobulin suppressor of T-cell activation'. But we knew that already. A novel target, 'VISTA potentially represents a new mechanism to treat a diverse range of tumours.' HMBD-002 has passed a phase I trial in the US, which showed the agent to be 'pharmacologically active" and generally safe and well-tolerated. 'After the challenges of recent months, we are once again a mid-clinical stage drug development business,' says Percheron CEO Dr James Garner. The 'challenges' refer to two board spills – both unsuccessful – after the company's Duchenne muscular dystrophy trial proved an unmitigated flop. Percheron shares this morning rebounded as much as 30%, or one-third of a cent. Neurizon eyes easier drug delivery While Paradigm goes from liquid to solid, Neurizon Therapeutics (ASX:NUZ) is moving the other way with its drug candidate to treat amyotrophic lateral sclerosis (ALS, a form of motor neurone disease). The liquid formulation of Neurizon's candidate NUZ-001 is designed to support patients with all stages of ALS, 'particularly those with swallowing difficulties such as bulbar onset'. The first manifestation of ALS, bulbar onset can lead to difficulties with speech (dysarthria), swallowing (dysphagia), and sometimes breathing. Neurizon will integrate the liquid form into its ongoing NUZ-001 program, starting with a human bioequivalence study in the first half of 2026. The company says the formulation resulted from direct feedback from patients and carers. 'As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing,' Neurizon chief Dr Michael Thurn says. Rainforest foraging leads to cancer drug hope The private, eternal IPO candidate Qbiotics has reported 'highly encouraging' results from a phase II study of its cancer therapy sourced from the Daintree rainforest. The trial targets soft tissue sarcoma, a rare cancer that generally forms as a painless lump (tumour) in any one of the soft tissues in the body. Qbiotics' candidate, tigilanol tiglate activates a certain protein to stimulate the immune system and destroy tumours. In stage one of the trial, ten evaluable patients achieved an objective response rate of 80%, 'based on the best observed response". In other words, eight out of ten evaluable patients saw either complete ablation or partial ablation (more than 30% reduction in volume) of treated tumours. Also, 22 of the 27 injected tumours across all patients showed complete or partial ablation (14 showing complete ablation). None of the 14 completely ablated tumours recurred at 6 months, "indicating tigilanol tiglate may provide durable responses". 'Given soft tissue sarcoma is a challenging cancer to treat, achieving this level of clinical activity is highly encouraging," Qbiotics chief Stephen Doyle says. Now moving to expanded stage two, the trial is being carried out at New York's Memorial Sloan Kettering Cancer Center. Eureka! moment Qbiotics founder Dr Gordon and her forest ecologist husband Dr Paul Reddell stumbled on the therapeutic benefits of tigilanol tiglate while fossicking in rainforest in the Atherton Tablelands of Far North Queensland. They observed that animals spat out the seed of the blushwood tree, pointing to a nontoxic deterrent preventing the critters from eating and thus destroying the seed.

ABC News
3 hours ago
- ABC News
How to limit the spread of COVID, cold and flu at home in winter
Winter can be a contagious time of year for everything from COVID-19 to the common cold. Once someone in your household feels the first ominous tickle at the back of their throat, everyone else can feel doomed to follow. "It's always a challenge within households because we know households are the place where viruses like respiratory viruses spread really efficiently," says Catherine Bennett, Deakin University's chair of epidemiology. But there are ways to limit the risk of illnesses spreading from one family member or housemate to another, she says. Professor Bennett says if someone within your household becomes sick, it is possible you have already been exposed before they had any symptoms. However, if the sick person can isolate from the rest of household it's still worth it, she says. Ideally this would look like using a separate bedroom and bathroom to others. She says this degree of isolation is not possible or realistic for many households. Isolation can also look like someone sleeping on the couch to "reduce their risk of inhaling the virus" from their unwell partner overnight, she says. Medical director for government-funded online public health information service Healthdirect Darran Foo says if possible, the symptomatic person should remain isolated from the rest of the household until they no longer have active symptoms. For example, "no more ongoing fevers, no more coughing up lots of phlegm". If someone in the household is symptomatic, and isolating completely is not possible, Professor Bennett says a mask can help protect the rest of the household. "Wearing a mask if you're unwell can reduce your risk of passing it on to other people." Dr Foo also advises wearing a mask if it's possible and practical, particularly if you live in a smaller home like an apartment. Dr Foo recommends throwing used tissues away immediately and avoiding sharing cups, plates and cutlery in the household when someone is unwell, whether from a cold or COVID-19. "The biggest thing really is to maintain good hygiene, especially good hand hygiene," Dr Foo says. "Lots of hand washing and using sanitisers as much as possible." Professor Benett also says you should "wash your own hands more often in between touching things, even around the home" when you or someone else is sick. She recommends wiping down commonly used surfaces — such as the bathroom — more often. Any surfaces where someone has coughed may have droplets over them, she says. Professor Bennett says "bugs do so well [in winter because] we can't air our houses out". Poor ventilation will make it easier for viruses to spread, but she says increasing air turnover and introducing outdoor air can help. Open doors and windows when you can "so it's not the same air pushing right through the household that's around the person who's unwell." Dr Foo also says the more ventilation you can get at home the better, while of course avoiding hypothermia. Dr Foo says "the general advice all remains the same" if someone in the household is potentially more vulnerable. However, he says people more at risk of becoming seriously unwell may want to consult their regular healthcare professional who knows their medical history. "It really depends on that person's risk, their comorbidities and what ongoing conditions they have — and also to identify whether it's appropriate to use antiviral medication at that point in time." Professor Bennett says being diligent with mask wearing, hand washing and sanitising surfaces is particularly worth doing if someone in the house is vulnerable. Professor Bennett says being up to date with COVID-19 and influenza vaccinations will offer another layer of protection. "If you can't avoid infection in the household — and that's the hardest place to do it — then actually having some protection from severe illness is really important in influenza." In larger shared households there are more people to bring viruses home and that extra protection from vaccination is even more important, "particularly from severe illness in the vulnerable people in our households", Professor Bennett says. Dr Foo also encourages people to stay up to date with their vaccinations, "especially their annual flu vaccination and their COVID booster shots". This is general information only. For personal advice, you should see a qualified medical practitioner.

ABC News
6 hours ago
- ABC News
Victorian poultry farmer recovering from 'devastating' bird flu outbreak
A Victorian farmer who had to kill more 500,000 chickens to control an outbreak of bird flu has detailed the financial and emotional cost of the "devastating" ordeal. Phillip Szepe and his wife, Jane Szepe, own Kinross Farms near Euroa in the state's north, where bird flu was detected on four separate free-range egg farms. The outbreak began in Febuary and was contained earlier this month. Mr Szepe said the loss of his chickens and the massive clean-up operation took an emotional and financial toll on his family and business. "It's been very emotional — our team were devastated and to see that loss of birds euthanased on such a scale is completely gut-wrenching and very traumatic," he said. "We took all possible precautions in terms of managing the welfare and biosecurity of our birds at all times … but it's been pretty tumultuous. Mr Szepe said the quarantine process was "like a scene out of CSI". "People were in full biohazard suits, washing down areas, which was pretty intimidating, but that's what's necessary to managing the response and ensure we contained the virus to that area," he said. When the business returns to full production by mid-September it will supply 1.2 million eggs per day to supermarkets. "Retail shelves are now a lot fuller than what they have been, reflecting the recovery process with some of the farms affected by the prior outbreak just coming back to full production," Mr Szepe said. Kinross Farms was in the process of being purchased by New South Wales-based egg producer Pace Farm at the time of the outbreak. The sale is expected to be finalised within weeks. "Pace Farms supported us getting back into production as soon as possible with replacement birds they had available and they'd had similar experiences in the past, so they knew what was involved and there's no one to blame for what eventuated," Mr Szepe said. Multiple variants of avian influenza are present in Australia's wild bird population and can spread into commercial poultry farms directly from chickens being exposed to wildlife or from poor biosecurity practices such as dirty footwear. Australia is the only continent that has not been hit with the H5N1 subtype of the disease, which is spreading among multiple animals internationally. Mr Szepe is acutely aware of the threat the strain poses. "All you need is wild ducks or waterfowl to frequent the ranging area and you've got the potential for transmission … we believe that's what happened, despite our best endeavours and leading edge technology," he said. "We also have artificial intelligence lasers that detect ducks and then frighten them away with a high-resolution light. "Any person who enters our farms has to go through a shower facility, leave street clothes outside and put on our uniforms and, if you have personal items such as a phone or glasses, they have to be UV sanitised."